Klacid Uno

Clarithromycin, the active ingredient in Klacid Uno, is a macrolide antibiotic presented as an oral tablet for oral use. It treats a range of bacterial infections, including respiratory, sinus, skin and soft‑tissue infections, and is used in combination regimens for Helicobacter pylori eradication and is generally prescribed for patients who require a broad‑spectrum agent.

GNH USA supplies Klacid Uno as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with established quality‑assurance processes and regulatory approvals across EU markets.

Clarithromycin is indicated for several bacterial infections affecting the respiratory, sinus, skin and gastrointestinal systems.

Community‑acquired pneumonia: effective in eliminating the causative bacteria and improving clinical outcomes. Acute bacterial sinusitis: reduces sinus inflammation and clears infection. Skin and soft‑tissue infections: treats cellulitis, erysipelas and other susceptible skin infections. Helicobacter pylori eradication: used as part of combination therapy to achieve bacterial eradication and ulcer healing. Other susceptible bacterial infections: provides coverage for a range of Gram‑positive and some Gram‑negative organisms.

Clarithromycin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset. - Diarrhea: loose stools. - Altered taste: metallic sensation. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Hepatotoxicity: liver enzyme elevation or jaundice. - QT prolongation: potential cardiac arrhythmia.

Before prescribing Klacid Uno, clinicians should consider several safety measures.

Liver function assessment: evaluate hepatic status before initiating therapy. Cardiac monitoring: avoid in patients with known QT prolongation or taking other QT‑prolonging drugs. Allergy check: contraindicated in individuals with a known macrolide hypersensitivity. Drug interaction review: assess concomitant medications that may be affected by CYP3A4 inhibition. Renal impairment adjustment: consider dose modification in severe renal dysfunction. Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Clarithromycin interacts with several medicines; understanding the level of risk guides clinical decisions.

Major Interactions (Avoid): - Cisapride: risk of serious cardiac arrhythmias. - Pimozide: may cause QT prolongation and ventricular tachycardia. - Ergotamine derivatives: can precipitate ergot toxicity. - Terfenadine: increased risk of fatal cardiac events.

Moderate Interactions (Monitor Closely): - Simvastatin and other CYP3A4 substrates: may increase statin plasma levels, risk of myopathy. - Warfarin: potential enhancement of anticoagulant effect, monitor INR. - Oral contraceptives: possible reduction in efficacy, advise alternative contraception.